LENZ Therapeutics, Inc. (LENZ) Misses Q4 EPS by 116c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mailGet Alerts LENZ Hot Sheet
Join SI Premium – FREE
LENZ Therapeutics, Inc. (NASDAQ: LENZ) reported Q4 EPS of ($1.16). Revenue for the quarter came in at $1.59 million.
For earnings history and earnings-related data on LENZ Therapeutics, Inc. (LENZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Linde (LIN) Tops Q3 EPS by 7c ; Offers Guidance
- AB InBev SA (BUD) Tops Q3 EPS by 7c
- LENZ Therapeutics cuts costs, changes CEO as VIZZ sales rise 50%
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
